The Rheumatology Drugs for COVID-19 Management: Which and When?
Open Access
- 16 February 2021
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (4), 783
- https://doi.org/10.3390/jcm10040783
Abstract
Introduction: While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-α, which hallmarks the most severe clinical cases. ‘Repurposing’ immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients.This publication has 121 references indexed in Scilit:
- Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virusVirology, 2011
- A Randomized Controlled Trial of Chloroquine for the Treatment of Dengue in Vietnamese AdultsPLoS Neglected Tropical Diseases, 2010
- Differentiation of Effector CD4 T Cell PopulationsAnnual Review of Immunology, 2010
- Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn MiceAntimicrobial Agents and Chemotherapy, 2009
- Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entryProceedings of the National Academy of Sciences of the United States of America, 2008
- Fcγ receptors as regulators of immune responsesNature Reviews Immunology, 2008
- Signals required for programming effector and memory development by CD8+ T cellsImmunological Reviews, 2006
- Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cellsBlood, 2005
- Review:IL-6 Transsignaling: TheIn VivoConsequencesJournal of Interferon & Cytokine Research, 2005
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990